{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:37:38Z","timestamp":1792687058931,"version":"4.5.0"},"reference-count":26,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: In July of 2021, the Brazilian National Ministry of Health integrated three months of once-weekly isoniazid plus rifapentine (3HP) into the National Guidelines for Tuberculosis Control as a first-line tuberculosis preventive therapy (TPT) option for people living with HIV (PLHIV) and tuberculosis household contacts (HHCs). As part of the Unitaid-sponsored Increasing Market and Public Health Outcomes through Scaling up Affordable Access Models of Short Course Preventive Therapy for TB project to implement short-course TPT, we evaluated 3HP uptake, completion, and tolerability among PLHIV and pediatric HHCs in Brazil. Methods: We conducted a multicenter single-arm pragmatic project to roll out 3HP for PLHIV and HHCs in the 2- to 14-year age bracket in the cities of Rio de Janeiro and Manaus, Brazil. Participants were identified, treated, and monitored in accordance with Brazilian national tuberculosis guidelines. De-identified patient-level data on treatment initiation, adverse events, and completion were collected and analyzed. Results: From October of 2021 to March of 2023, 380 PLHIV (77.6% of whom were male; median age, 40 years [IQR, 31-51]) and 74 HHCs (54.1% of whom were male; median age, 8.6 years [IQR, 5.1-11.8]) were enrolled in the study. Treatment completion rates were 83.7% among PLHIV and 82.4% among HHCs. Completion rates were higher in Rio de Janeiro than in Manaus (PLHIV: 86.0% vs. 79.6%; HHCs: 85.2% vs. 80.9%), although completion of 10 doses was similar (PLHIV: 86.4% vs. 86.1%). Adverse event-related discontinuation was low (PLHIV: 2.4%; HHCs: 2.7%). One person living with HIV developed active tuberculosis during treatment. At six months of follow-up, 99.6% of the PLHIV remained free of tuberculosis. Conclusions: The 3HP regimen was successfully introduced, had high treatment completion rates, and was well tolerated. Widespread use of 3HP for TPT may accelerate tuberculosis elimination in Brazil.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20250125","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:22:41Z","timestamp":1757517761000},"page":"e20250125","source":"Crossref","is-referenced-by-count":1,"title":["Treatment completion and challenges in rolling out 12-dose weekly rifapentine plus isoniazid to prevent tuberculosis among people living with HIV and pediatric household contacts in Brazil"],"prefix":"10.36416","author":[{"given":"Isadora","family":"Salles1","sequence":"first","affiliation":[{"name":"1. Center for Tuberculosis Research, Johns Hopkins University, Baltimore (MD) USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamile","family":"Garcia de Oliveira2","sequence":"additional","affiliation":[{"name":"2. Secretaria Municipal de Sau\u00b4de do Rio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Brito de Souza3","sequence":"additional","affiliation":[{"name":"3. Fundac\u00b8a~o de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus (AM) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cohn1","sequence":"additional","affiliation":[{"name":"1. Center for Tuberculosis Research, Johns Hopkins University, Baltimore (MD) USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Spener-Gomes4,5","sequence":"additional","affiliation":[{"name":"5. Departamento de Sa\u00fade Coletiva, Faculdade de Medicina, Universidade Federal do Amazonas, Manaus (AM) Brasil. 6. Funda\u00e7\u00e3o Oswaldo Cruz - Fiocruz - Rio de Janeiro (RJ) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Dourado de Andrade3","sequence":"additional","affiliation":[{"name":"3. Fundac\u00b8a~o de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus (AM) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Saraceni2","sequence":"additional","affiliation":[{"name":"2. Secretaria Municipal de Sau\u00b4de do Rio de Janeiro, Rio de Janeiro (RJ) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Cesar Cavalcante2,6","sequence":"additional","affiliation":[{"name":"2. Secretaria Municipal de Sau\u00b4de do Rio de Janeiro, Rio de Janeiro (RJ) Brasil. 6. Funda\u00e7\u00e3o Oswaldo Cruz - Fiocruz - Rio de Janeiro (RJ) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Weiser7","sequence":"additional","affiliation":[{"name":"7. The Aurum Institute, Johannesburg, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makaita","family":"Gombe7","sequence":"additional","affiliation":[{"name":"7. The Aurum Institute, Johannesburg, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violet","family":"Chihota7,8,9","sequence":"additional","affiliation":[{"name":"7. The Aurum Institute, Johannesburg, South Africa. 8. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. 9. Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville (TN) USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Churchyard7,8,9","sequence":"additional","affiliation":[{"name":"7. The Aurum Institute, Johannesburg, South Africa. 8. School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. 9. Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville (TN) USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"E Chaisson1","sequence":"additional","affiliation":[{"name":"1. Center for Tuberculosis Research, Johns Hopkins University, Baltimore (MD) USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Cordeiro-Santos3,4,10","sequence":"additional","affiliation":[{"name":"3. Fundac\u00b8a~o de Medicina Tropical Dr. Heitor Vieira Dourado, Manaus (AM) Brasil. 4. Programa de P\u00f3s-Gradua\u00e7\u00e3o em Medicina Tropical, Universidade do Estado do Amazonas, Manaus (AM) Brasil. 10. Faculdade de Medicina, Universidade Nilton Lins, Manaus (AM) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betina","family":"Durovni2,11","sequence":"additional","affiliation":[{"name":"2. Secretaria Municipal de Sau\u00b4de do Rio de Janeiro, Rio de Janeiro (RJ) Brasil. 11. Universidade Federal do Rio de Janeiro, Rio de Janeiro (RJ) Brasil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1.           World Health Organization (WHO) [homepage on the Internet]. Geneva: WHO; c2024 [cited 2025 Feb 1]. Global tuberculosis report 2024. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2024","DOI":"10.1016\/j.jctube.2025.100522"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.           World Health Organization. WHO global lists of high-burden countries for tuberculosis (TB), TB\/HIV, and multidrug\/rifampicin-resistant TB (MDR\/RR-TB), 2021-2025: background document. Geneva, Switzerland: WHO; 2021.","DOI":"10.1183\/1393003.congress-2017.oa1944"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.           Minist\u00e9rio da Sa\u00fade. [homepage on the Internet]. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; c2024 [cited 2025 Feb 1]. Boletim Epidemiol\u00f3gico de Tuberculose - N\u00famero Especial. Mar. 2024. Available from: https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/boletins-epidemiologicos\/2024\/boletim-epidemiologico-tuberculose-2024\/view","DOI":"10.51161\/iii-conasc\/57403"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.           Gunasekera KS, Vonasek B, Oliwa J, Triasih R, Lancioni C, Graham SM, et al. Diagnostic challenges in childhood pulmonary tuberculosis-optimizing the clinical approach. Pathogens. 2022 23;11(4):382. https:\/\/doi.org\/10.3390\/pathogens11040382","DOI":"10.3390\/pathogens11040382"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.           Maphalle LNF, Michniak-Kohn BB, Ogunrombi MO, Adeleke OA. Pediatric tuberculosis management: a global challenge or breakthrough? Children (Basel). 2022;9(8):1120. https:\/\/doi.org\/10.3390\/children9081120","DOI":"10.3390\/children9081120"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.           Whittaker E, L\u00f3pez-Varela E, Broderick C, Seddon JA. Examining the complex relationship between tuberculosis and other infectious diseases in children. Front Pediatr. 2019;7:233. https:\/\/doi.org\/10.3389\/fped.2019.00233","DOI":"10.3389\/fped.2019.00233"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.           Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS. 2021;32(9):780-790. https:\/\/doi.org\/10.1177\/0956462421992257","DOI":"10.1177\/0956462421992257"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.           Pinto PFPS, Teixeira CSS, Ichihara MY, Rasella D, Nery JS, Sena SOL, et al. Incidence and risk factors of tuberculosis among 420,854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004-18): a cohort study. Lancet Infect Dis. 2024;24(1):46-56. https:\/\/doi.org\/10.1016\/S1473-3099(23)00371-7","DOI":"10.1016\/s1473-3099(23)00371-7"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9.           Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health.2013;34:271-86. https:\/\/doi.org\/10.1146\/annurev-publhealth-031912-114431","DOI":"10.1146\/annurev-publhealth-031912-114431"},{"key":"ref9","unstructured":"10.        World Health Organization. Global tuberculosis report, 2023. Geneva, Switzerland: WHO; 2023."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.        Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. 2016;16(11):1269-1278. https:\/\/doi.org\/10.1016\/S1473-3099(16)30216-X","DOI":"10.1016\/s1473-3099(16)30216-x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.        Kendall EA, Durovni B, Martinson NA, Cavalcante S, Masonoke K, Saraceni V, et al. Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV. AIDS. 2020;34(1):63-71. https:\/\/doi.org\/10.1097\/QAD.0000000000002380","DOI":"10.1097\/qad.0000000000002380"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.        Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ. Interventions for improving adherence to treatment for latent tuberculosis infection: A systematic review. BMC Infect Dis. 2016;16:257. https:\/\/doi.org\/10.1186\/s12879-016-1549-4","DOI":"10.1186\/s12879-016-1550-y"},{"key":"ref13","unstructured":"14.        World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva, Switzerland: WHO; 2018."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.        Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-66. https:\/\/doi.org\/10.1056\/NEJMoa1104875","DOI":"10.1056\/nejmoa1104875"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.        Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol. 2019;188(12):2078-2085. https:\/\/doi.org\/10.1093\/aje\/kwz172","DOI":"10.1093\/aje\/kwz172"},{"key":"ref16","unstructured":"17.        World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Geneva, Switzerland: WHO; 2022."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.        Brasil. Minist\u00e9rio da Sa\u00fade. Nota Informativa No 5\/2021-CGDR\/DCCI\/SVS\/MS - Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2021. Available from: https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/notas-informativas\/2021\/nota-informativa-no-5-2021-cgdr-dcci-svs-ms-1\/view","DOI":"10.5327\/dst-2177-8264-202335s1272"},{"key":"ref18","unstructured":"19.        Vicari T, Lago LM, Bulgarelli AF. Realities of the practices of the Family Health Strategy as driving forces for access to SUS health services: a perspective of the Institutional Analysis. Saude Debate. 2022;46(132):135-46. https:\/\/doi.org\/10.1590\/0103-1104202213209"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.        G\u00f3mez EJ, Jungmann S, Lima, AS. Resource allocations and disparities in the Brazilian health care system: insights from organ transplantation services. BMC Health Serv Res. 2018;18:90. https:\/\/doi.org\/10.1186\/s12913-018-2851-1","DOI":"10.1186\/s12913-018-2851-1"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.        Miranda ALDC, Costa VLDS, da Paix\u00e3o ART, Martins MB, Polaro SHI, Cunha CLF, et al. Factors associated with access to health services among people with long COVID in the Brazilian Amazon. Front Public Health. 2024;12:1503907. https:\/\/doi.org\/10.3389\/fpubh.2024.1503907","DOI":"10.3389\/fpubh.2024.1503907"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.        Brasil. Minist\u00e9rio da Sa\u00fade. Nota Informativa No 2\/2024-CGTM\/DATHI\/SVSA\/MS - Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infec\u00e7\u00f5es Sexualmente Transmiss\u00edveis. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2024. Available from: https:\/\/www.gov.br\/aids\/pt-br\/central-de-conteudo\/notas-informativas\/2025\/nota-informativa-no-2_2024-cgtm_dathi_svsa_ms.pdf\/view","DOI":"10.5327\/dst-2177-8264-202335s1272"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.        Golhen K, Buettcher M, Kost J, Huwyler J, Pfister M. Meeting challenges of pediatric drug delivery: The potential of orally fast disintegrating tablets for infants and children. Pharmaceutics. 2023;15(4):1033. https:\/\/doi.org\/10.3390\/pharmaceutics15041033","DOI":"10.3390\/pharmaceutics15041033"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.        Khatri A, Verma M, Patidar AB, Kumari P, Akram H. Evaluating the challenges of oral drug administration in children: a review. Int J Contemp Pediatr. 2025;12(5):865-9. https:\/\/doi.org\/10.18203\/2349-3291.ijcp20251115","DOI":"10.18203\/2349-3291.ijcp20251115"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.        Maciel ELN, Sanchez MN, Cruz AMD, Cravo Neto DB, Lima NVT. Brazil\u2019s pivotal moment in public health: establishing the Interministerial Committee (CIEDDS) for the elimination of tuberculosis and socially determined diseases. Rev Soc Bras Med Trop. 2024;57:e006012024. https:\/\/doi.org\/10.1590\/0037-8682-0597-2023","DOI":"10.1590\/0037-8682-0597-2023"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.        Brasil. Imprensa Nacional. Decreto No 11.494, de 17 de abril de 2023. DOU Ed. 74, Se\u00e7\u00e3o 1, p.14. Bras\u00edlia: Imprensa Nacional DOI; 2023. Available from: https:\/\/www.in.gov.br\/en\/web\/dou\/-\/decreto-n-11.494-de-17-de-abril-de-2023-477625680","DOI":"10.33871\/22386084.2023.12.24.426-444"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:22:43Z","timestamp":1757517763000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/4146\/en-US"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":26,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20250125","relation":{},"ISSN":["1806-3756"],"issn-type":[{"value":"1806-3756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}